| Autor: |
James Emmanuel San, Koleka Mlisana, Vicky L Baillie, Richard J Lessells, Tulio de Oliveira, Thabo Mohale, Zamantungwa T. H. Khumalo, Carolyn Williamson, Noxolo Ntuli, Prudence Kgagudi, Wolfgang Preiser, Wesley C. Van Voorhis, Josie Everatt, Shabir A. Madhi, Anele Mnguni, Florette K. Treurnicht, Cathrine Scheepers, Bronwen E. Lambson, Sureshnee Pillay, Nicole Wolter, Linda-Gail Bekker, Nelia P. Manamela, Penny L. Moore, Yeshnee Naidoo, Zinhle Makatini, Daniel G. Amoako, Nokukhanya Msomi, Jennifer Giandhari, Anne von Gottberg, Sandile Cele, Alex Sigal, Marietje Venter, Arshad Ismail, Houriiyah Tegally, Nei-yuan Hsiao, Eduan Wilkinson, Constantinos Kurt Wibmer, Tongai Maponga, Glenda Gray, Jinal N. Bhiman, Boitshoko Mahlangu, Gaurav Kwatra, Simone I. Richardson, Darren P. Martin, Upasana Ramphal |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Global genomic surveillance of SARS-CoV-2 has identified variants associated with increased transmissibility, neutralization resistance and disease severity. Here we report the emergence of the PANGO lineage C.1.2, detected at low prevalence in South Africa and eleven other countries. The emergence of C.1.2, associated with a high substitution rate, includes changes within the spike protein that have been associated with increased transmissibility or reduced neutralization sensitivity in SARS-CoV-2 VOC/VOIs. Like Beta and Delta, C.1.2 shows significantly reduced neutralization sensitivity to plasma from vaccinees and individuals infected with the ancestral D614G virus. In contrast, convalescent donors infected with either Beta or Delta showed high plasma neutralization against C.1.2. These functional data suggest that vaccine efficacy against C.1.2 will be equivalent to Beta and Delta, and that prior infection with either Beta or Delta will likely offer protection against C.1.2. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
